Clinical Trial Update: Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing subcutaneous pasireotide (SOM230) with subcutaneous octreotide (Sandostatin) in adults with acromegaly has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• SOM230 (pasireotide)
• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 2 | Status: COMPLETED